EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
What Changes at Scale, and How Do You Know?
A pharmaceutical process that performs reliably on a few grams of material can behave very differently at pilot or commercial scale The temperature setpoint that worked on the bench the mixing time that delivered a uniform blend the feed rate that kept a reaction on track none of these is guaranteed to mean the same thing in larger equipment When that difference goes...
Advisory Board
KNOWLEDGE BANK
-
Articles
Advancing Pharmacovigilance Talent for AI: Overcoming Skills and Resource Barriers
In the transforming field of pharmacovigilance PV artificial intelligence AI is reshaping how drug safety is monitored and managed As PV evolves from manual reactive workflows to sophisticated AIaugmented systems the imperative for comprehensive workforce upskilling grows stronger Organisations and professionals must adapt to new technical demands regulatory requirements and ethical challenges to...
B2B Pharma Editorial Opportunities: Boosting Brand Visibility in Industry Magazines
The teams which previously counted greatly on banner advertisements email newsletters and sponsorship of various events are beginning to reevaluate the source of true influence Since such channels have a role to play they seldom earn credibility alone In contrast a wellplaced article in a respected industry publication can do something most campaigns struggle to achieveit makes people take you ser...
The Rise of Personalized Medicine in Europe: Opportunities and Challenges for Pharma Companies
In Europe there is a growing momentum around personalized medicine an inventive method that customizes medical treatments based on individual characteristics As progress in genomics and molecular diagnostics advances
Business Transformation Strategies for the Pharmaceutical Industry
The pharmaceutical industry is at a crossroads Drug development timelines remain long regulatory scrutiny keeps intensifying and patients now expect the same seamless digital experiences they get from banking apps or online retailers Against this backdrop pharma business transformation has moved from a nicetohave to a survival requirement
Revolutionizing Healthcare: Gene Editing for Genetic Disorders with CRISPR Technology
Gene editing using CRISPR Clustered Regularly Interspaced Short Palindromic Repeats technology has the potential to revolutionize healthcare particularly in addressing genetic disorders
Therapeutic Intervention of Polymeric Nanoparticles Combining Bone Marrow Stem Cells for the treatment of Alzheimer’s disease
Alzheimers disease ADis a neurological disorder that is responsible for brain atrophy and neuronal degeneration resulting in a decline in thinking ability and behaviour The progressive neurodegeneration leads to memory loss or dementia which makes it difficult to carry out daytoday tasks and it also has an impact on the socializing ability of the individual
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
B2B Pharma Editorial Opportunities: Boosting Brand Visibility in Industry Magazines
Kate Williamson
B2B pharma editorial opportunities provide a reputable means of creating brand awareness via industry magazines. Through sponsored content and guest articles, companies are able to exchange knowledge,...
-
2
The Rise of Personalized Medicine in Europe: Opportunities and Challenges for Pharma Companies
Kate Williamson
This article explores the burgeoning landscape of personalized medicine in Europe, presenting pharmaceutical companies with opportunities like targeted therapies and market expansion. It delves into s...
-
3
Business Transformation Strategies for the Pharmaceutical Industry
Kate Williamson
Pharmaceutical companies face mounting pressure from regulatory shifts, patent cliffs, and rising R&D costs. This article explores proven pharma business transformation strategies, digital transfo...
-
4
Revolutionizing Healthcare: Gene Editing for Genetic Disorders with CRISPR Technology
Harry Callum
CRISPR technology, with its precision in gene editing, revolutionizes healthcare by enabling personalized treatments for genetic disorders. It’s potential for correcting mutations, therapeutic a...
-
5
Therapeutic Intervention of Polymeric Nanoparticles Combining Bone Marrow Stem Cells for the treatment of Alzheimer’s disease
Ruchi Chawla
Varsha Rani
Mohini Misra
Krishan Kumar
Dementia is the first sign of neuronal impairment related to Alzheimer’s disease (AD). The neurodegeneration initially appears in the hippocampus and cortex which comprises memory developing are...
press releases Read more...
Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development
Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX a potential firstinclass small molecule modulator of MYC condensates into clinical development
Instem and Histofy Launch Provantis® Compose, Accelerating Nonclinical Study Reporting Through AI-Assisted Automation and Expert Oversight
Instem a leading provider of software for life sciences research and regulatory operations across preclinical and clinical RD today announced a strategic partnership with Histofy to launch Provantis Compose a powerful new module designed to automate and accelerate the creation of final study reports...
Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
Rosemont Pharmaceuticals Holdings Inc Rosemont a global specialty pharmaceutical company focused on designing and delivering medicines around patients needs today announced that it has entered into a definitive merger agreement
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
Asimov the company building an AInative synthetic biology platform to advance therapeutic development and Emergent Biosolutions NYSE EBS a leading global public health company today announced a cell line development partnership
Events Read more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
LATEST NEWS Read more...
Erasca Partners with Bristol Myers Squibb to Study ERAS-0015 Combination Therapy for Pancreatic Cancer
Erasca Inc a clinicalstage precision oncology company focused on developing treatments for cancers driven by the RASMAPK signalling pathway has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS
Libtayo Receives EU Approval for Extended Dosing and Shorter Infusion Times Across Six Cancer Indications
Regeneron Pharmaceuticals has received European Commission EC approval for an alternative dosing schedule for Libtayo cemiplimab across all six of its approved indications for skin lung and cervical cancers in the European Union EU
FDA approves Roche’s Wilserdly for ER-positive, ESR1-mutated advanced breast cancer
Roche has received approval from the US Food and Drug Administration FDA for Wilserdly giredestrant in combination with everolimus to treat adults with oestrogen receptor ERpositive human epidermal growth factor receptor HERnegative ESRmutated locally advanced or metastatic breast cancer
European Commission approves Revolution Medicines’ RASONQUE for metastatic pancreatic cancer
Revolution Medicines has received European Commission EC approval for RASONQUE daraxonrasib to treat adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy The medicine is taken once daily as an oral tablet and is approved for patients with or witho...
Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer
Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN
Takeda Launches ORZEYFUL (Oveporexton), the First Orexin Agonist for Narcolepsy Type 1, in the US
Takeda TSE NYSE TAK has announced the US launch of ORZEYFUL oveporexton CIV now available by prescription for adults with narcolepsy type NT also known as narcolepsy with cataplexy The medicine is the first and only orexin agonist available for this condition








